Special Issue "Vaccination and Autoimmune Inflammatory Rheumatic Diseases"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 June 2023 | Viewed by 696

Special Issue Editor

Medical Clinic III: Endocrinology, Nephrology and Rheumatology, University Hospital Leipzig, Leipzig, Germany
Interests: vaccination (effectiveness, epidemiology); autoimmune inflammatory rheumatic diseases; immunosuppressive therapy; SARS-CoV-2; ANCA-associated vasculitis

Special Issue Information

Dear Colleagues,

The vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRDs) remains challenging. Despite the often substantially increased risk for infections, the reported vaccination rates for important vaccines (e.g., influenza) are low. In this context, concerns about the triggering of flare-ups of known AIIRDs or the induction of autoimmunity itself are prominent. Furthermore, vaccination effectiveness seems to be impaired because of immunosuppressive or immunomodulatory therapy.

This Special Issue addresses all aspects of vaccination related to autoimmune inflammatory rheumatic diseases. Topics include, but are not limited to, reports on vaccination efficacy under immunosuppressive therapy, autoimmune-related side effects and AIIRD flare-up induction due to vaccination, studies investigating the reasons for vaccination hesitancy or manuscripts on patient education regarding vaccination in immunocompromised patients with autoimmune inflammatory rheumatic diseases.   

All kinds of papers, including original articles, reviews, meta-analyses and theoretical contributions are welcomed.

Dr. Marco L. Krasselt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • vaccination
  • autoimmune inflammatory rheumatic diseases
  • vaccination rates
  • vaccination efficacy
  • vaccination hesitancy
  • varicella zoster virus
  • influenza
  • SARS-CoV-2
  • flare induction
  • triggering of autoimmunity

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Brief Report
Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases
Vaccines 2023, 11(4), 760; https://doi.org/10.3390/vaccines11040760 - 29 Mar 2023
Viewed by 560
Background: Vaccination rates are known to be low in patients with autoimmune inflammatory rheumatic diseases (AIIRD). We therefore aimed to determine current vaccination rates against influenza, Streptococcus pneumoniae and herpes zoster in a cohort of patients with AIIRD in Germany. Methods: Consecutive adult [...] Read more.
Background: Vaccination rates are known to be low in patients with autoimmune inflammatory rheumatic diseases (AIIRD). We therefore aimed to determine current vaccination rates against influenza, Streptococcus pneumoniae and herpes zoster in a cohort of patients with AIIRD in Germany. Methods: Consecutive adult patients with an AIIRD were recruited from our outpatient clinic during their regular consultations. The individual vaccination status regarding influenza, Streptococcus pneumoniae and herpes zoster was obtained by reviewing the vaccination documents. Results: A total of 222 AIIRD patients (mean age 62.9 ± 13.9 years) were included. In total, 68.5% were vaccinated against influenza, 34.7% against Streptococcus pneumoniae and 13.1% against herpes zoster (HZ). The pneumococcal vaccination was outdated in 29.4% of the vaccinated patients. Vaccination rates were significantly higher in patients ≥60 years old (odds ratio (OR) 2.167, 95% confidence interval (CI) 1.213–3.870, p = 0.008 for influenza, OR 4.639, 95% CI 2.555–8.422, p < 0.0001 for pneumococcal and OR 6.059, 95% CI 1.772–20.712, p = 0.001 for HZ vaccination). Ages > 60 years, female sex, glucocorticoid use and influenza vaccination were all independently associated with a pneumococcal vaccination. Regarding influenza vaccination, only a positive pneumococcal vaccination history remained independently associated. In patients with HZ vaccination, glucocorticoid use and a preceding pneumococcal vaccination were independently associated with HZ protection. Conclusions: The frequencies of vaccinations against influenza, Streptococcus pneumoniae and HZ have increased during recent years. While this can be partly explained by continuous efforts in patient education during the outpatient visits, the COVID-19 pandemic might also have contributed. Nevertheless, the persistently high incidence and mortality of these preventable diseases in patients with AIIRDs mandates further efforts to increase vaccination coverage, particularly in SLE patients. Full article
(This article belongs to the Special Issue Vaccination and Autoimmune Inflammatory Rheumatic Diseases)
Back to TopTop